P53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder

British Journal of Cancer

Volumn 71, Issue 1, 1995, Pages 201-205

  Serth, J ^a   Kuczyk, M A ^a   Bokemeyer, C ^a   Hervatin, C ^a   Nafe, R ^a   Tan, H K ^a   Jonas, U ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

P53 tumour suppressor gene; Prognostic factors; Superficial bladder cancer

Indexed keywords

CYCLINE; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; BLADDER IRRIGATION; CANCER GRADING; CANCER INVASION; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SEX DIFFERENCE; STAINING; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGE; PROGNOSIS; PROTEIN P53; SURVIVAL RATE;

EID: 0028861211     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.41     Document Type: Article

References (36)

1. BANKS L. MATLASHEWSKI G AND CRAWFORD L. (1986). Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 159, 529–534.
2. BISCHOFF JR, FRIEDMAN PN, MARSHAK DR, PRIVES C AND BEACH D. (1990). Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Natl. Acad. Sci. USA, 87, 4766-4770.
3. BOKEMEYER C, KUCZYK MA AND SERTH J. (1994). p53 - immuno- histochemistry as a prognostic marker in superficial bladder cancer. N. Engl. J. Med.(in press).
4. BORLAND RN, BRENDLER CB AND ISAACS WB (1992). Molecular biology of bladder cancer. Hematol. Oncol. Clin. N. Am., 6, 31-39
5. DALBAGNI G, SAEZ GT, OLIVA MR, PELLICER A, REUTER VE, FAIR WR AND CORDON-CARDO C. (1993). P53 mutations in bladder cancer correlation between immunohistochemistry (IHC), single strand conformation polymorphism (SSCP) and sequencing. J. Urol., 149, 238A.
6. FINLAY CA, HINDS PW, TAN TH, ELIYAHU D, OREN M AND LEVINE AJ. (1988). Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half-life. Mol. Cell Biol., 8, 531-539.
7. FINLAY CA, HINDS PW AND LEVINE AJ, (1989). The p53 protooncogene can act as a suppressor of transformation. Cell, 57, 1083-1093.
8. GAZDAR AF. (1992). Molecular markers for the diagnosis and prognosis of lung cancer. Cancer, 69, 1592-1599.
9. GERDES J. (1990). Ki-67 and other proliferation markers useful for immunohistochemical diagnostic and prognostic evaluations in human malignancies. Semin. Cancer Biol., 1, 199-206.
10. HAMILTON SR. (1992). Molecular genetics of colorectal cancer. Cancer, 70, 1216-1221.
11. HARRIS AL. (1992). p53 expression in human breast cancer. Adv. Cancer Res., 59, 69-88.
12. HARRIS CC AND HOLLSTEIN M. (1993). Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329, 1318-1327.
13. HOFSTADTER F, DELGADO R, JAKSE G AND JUDMEIER W. (1986). Urothelial dysplasia and carcinoma in situ of the bladder. Cancer, 57, 356-361.
14. HORAK E, SMITH K, BROMLEY L, LE JEUNE S, GREENALL M, LANE D AND HARRIS AL. (1991). Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene, 6, 2277-2284.
15. JAKSE G, RAUSCHMEIER H, ROSMANITH P AND HOFSTADTER F. (1983). Determination of carcinoembryonic antigen in tissue, serum and urine in patients with transitional cell carcinoma of the urinary bladder. Urol. Int., 38, 121-125.
16. JENKINS JR, RUDGE K AND CURRIE GA. (1984). Cellular immortalisation by a cDNA clone encoding the transformation associated phosphoprotein p53. Nature, 312, 651-654.
17. KUCZYK MA, SERTH J, BOKEMEYER C, HERVATIN C, THON WF, ALLHOFF EP AND JONAS U. (1993). Immunhistochemischer Nachweis des p53-Proteins als Prognosefaktor für den klinischen Verlauf von Hamblasentumoren. Akt. Urol.JA, 351-356.
18. LANE DP AND CRAWFORD LV. (1979). T-antigen is bound to host protein in SV40-transformed cells. Nature, 278, 261-263.
19. LIPPONEN PK AND ESKELINEN MJ (1992a). Cell proliferation of transitional bladder cancer determined by PCNA/cyclin immunostaining. Anticancer Res., 12, 577-583.
20. LIPPONEN PK AND ESKELINEN MJ. (1992b). Cell proliferation of transitional cell bladder tumours by PCNA cyclin immunostaining and its prognostic value. Br. J. Cancer, 66, 171-176.
21. LOGOTHETIS CJ, XU HJ, RO JH, HU SX, SAHIM A, ORDONEZ N AND BENEDICT WF. (1992). Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl Cancer Inst., 84, 1256-1261.
22. POCOCK RD, PONDER BAJ, O’SULLIVAN JPO, IBRAHIM SK, EASTON DF AND SHEARER RJ. (1982). Prognostic factors in non-infiltrating carcinoma of the bladder: a preliminary report. Br. J. Urol., 54, 711-715.
23. QUINLAN DC, DAVIDSON AG, SUMMERS CL, WARDEN HE AND DOSHI HM. (1992). Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52, 4828-4831.
24. SARKIS AS, DALBAGNI G, CORDON-CARDO C, ZHANG ZF, SHEINFELD J, FAIR WR, HERR HW AND REUTER VE. (1993a). Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl Cancer Inst., 85, 53-59.
25. SARKIS AS, CORDON-CARDO C, REUTER VR, HERR HW, ZHANG Z-F, MELAMED J, SCHULTZ P, BAJORIN D, FAIR WR AND SCHER HI. (1993b). P53 overexpression in patients with invasive bladder cancer treated with neoadjuvant methotrexate, vinblastine, adriamycin. and cisplatin (M-VAC). Proc. ASCO, 249A.
26. SIDRANSKY D, ESCHENBACH A, TSAI YC, JONES P, SUMMER-HAYES I, MARSHALL F, PAUL M, GREEN P, HAMILTON SR, FROST P AND VOGELSTEIN B. (1991). Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252, 706-709.
27. SIDRANSKY D, FROST P, ESCHENBACH A, OYASU R, PREISINGER AC AND VOGELSTEIN B. (1993). Clonal origin of bladder cancer. V. Engl. J. Med. 326, 737-740.
28. SPRUCK III CH, RIDEOUT WM, OLUMI AF, OHNESEIT PF, YANG AS, TSAI YC, NICHOLS PN, HORN T, HERMANN GG, STEVEN IT, ROSS AK, YUM C AND JONES PA (1993). Distinct pattern of p53 mutations in bladder cancer, relationship to tobacco usage. Cancer Res., 53, 1162-1166.
29. STARZYNSKA T, BROMLEY M, GHOSH A AND STERN PL. (1992). Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br. J. Cancer, 66, 558-562.
30. SUMMERS JL, COON JS, WARD RM, FALOR WH, MILLER AO AND WEINSTEIN RS. (1983). Prognosis in carcinoma of the urinary bladder based upon tissue blood group ABH AND Thomsen-Friedenreich antigen status and karyotype of the initial tumor. Cancer Res., 431, 934-939.
31. THOR AD, MOORE DH II, EDGERTON SM, KAWASAKI ES, REIHSAUS E, LYNCH HT, MARCUS JN, SCHWARTZ L, CHEN LC, MAY ALL BH AND SMITH HS. (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst., 84, 845-854.
32. TORTI FM AND LUM BL. (1987). Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy. Cancer, 59, 613-616.
33. TUBIANA M AND COURDI A (1989). Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother. Oncol., 15, 1-18.
34. VISAKORPI T, KALLIONIEMI OP, HEIKKINEN A KOIVULA T AND ISOLA J. (1992). Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl Cancer Inst., 84, 883-887.
35. WAASEM H AND LANE DP. (1990). Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA): structural conversation and the detection of a nucleolar form. J. CeU Sci., 90, 121-129.
36. WRIGHT C, MELLON K, JOHNSTON P, LANE DP, HARRIS AL, HORNE CH AND NEAL DE. (1991). Expression of mutant p53, c-erbBb-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer, 63, 967-970.